The 2025-2026 Research-Peptide Vendor Shutdown Wave: Who Closed and What It Signals

The closures clustered in a roughly nine-month window, according to trade coverage of the sector. Two of the most-trafficked names — Science.bio and Peptide Sciences — exited within weeks of one another in early 2026. The verifiable sequence is that Science.bio announced its permanent closure first (January 27, 2026), and Peptide Sciences followed with an abrupt shutdown on March 6, 2026; trade reporting describes Peptide Sciences as a high-volume operation, with figures of roughly $7.4 million in monthly online sales cited in secondary coverage (unverified against any primary source). The exits were not uniform: some were described as voluntary wind-downs, while at least one followed criminal prosecution.

Vendor-by-vendor details beyond the level of regulator and court records should be treated as trade-reported rather than primary-sourced. The verifiable anchors are the federal actions: the Amino Asylum guilty pleas, the FDA warning-letter wave, and the CBP interdiction described later in this article. Self-announced closure dates for Science.bio and Peptide Sciences are corroborated by multiple secondary outlets but are not regulator filings.

The consolidation was not a single event but the intersection of three enforcement and litigation vectors that each raised the operating cost and legal exposure of the gray-market model.

• FDA enforcement escalation: In September 2025 the FDA issued more than 50 warning letters. A central theme was products sold as 'research use only' (RUO) where the advertising indicated the product was intended for human use — a framing the agency treated as evidence the RUO label was pretextual. Named substances spanned GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) plus BPC-157 and SARMs [2].
• Border interdiction: According to CBP and contemporaneous reporting, U.S. Customs and Border Protection at the Port of Cincinnati uncovered a smuggling scheme in which shipments from China were mis-manifested. Officers identified more than 300 master cartons, each concealing roughly 15 prelabeled shipments, totaling about 5,000 individual peptide shipments — including retatrutide, semaglutide, tirzepatide, MOTS-c, semax and cagrilintide [1]. Reported coverage of the scheme appeared in early April 2026; the precise seizure window should be confirmed against the primary CBP release.
• Manufacturer litigation: Eli Lilly and Novo Nordisk pursued lawsuits in 2025 against compounders and large-scale sellers of GLP-1 products. A compounder later filed an antitrust countersuit alleging a coordinated crackdown — underscoring that the GLP-1 supply fight had moved firmly into the courts [6][8].

Much of the pressure traces to the FDA's bulk drug substance lists for compounding. Substances placed in Category 2 of the Section 503A list are flagged as having significant safety concerns, which effectively bars licensed compounding pharmacies from preparing them. BPC-157 is a documented example: according to STAT reporting, the FDA treats it as an unapproved drug and, in 2023, moved to prohibit compounding pharmacies from supplying it, citing potential significant safety risks [3].

The category picture is dynamic, not static. On April 15, 2026 the FDA gave notice that it would remove 12 peptide bulk drug substances from Category 2 — but, per legal analysis of the notice, only because the nominators withdrew their nominations, not because the substances were affirmatively cleared. Removal from the 'safety concerns' category does not equal compounding approval; the Pharmacy Compounding Advisory Committee (PCAC) is separately reviewing peptides for possible placement on the Category 1 503A Bulks List [4][5]. For sourcing analysis, the takeaway is that regulatory status is per-substance and time-sensitive, and a vendor's catalog can fall on either side of an enforcement line.

The enforcement wave repeatedly intersected with specific molecular and quality facts rather than abstract policy. Retatrutide, for instance, is an investigational drug, which is why the warning-letter framework described it as not eligible for compounding [2]. The BPC-157 evidence base is, per STAT reporting, unusually thin: almost all existing data on the peptide is described as deriving from a single research group, and the FDA has cited concerns including potential immunogenicity and incomplete safety information [3]. Identity and purity failures compound the legal risk — the Amino Asylum case turned in part on products labeled as SARMs that, according to reporting on the federal case, contained testosterone, a controlled substance, illustrating how mislabeling can convert a regulatory problem into a criminal one.

The structural result described across trade coverage is fewer, larger suppliers and a thinner long tail. From a verification standpoint, that has practical consequences for laboratory researchers evaluating a source: the disappearance of an established storefront does not transfer its quality history to whoever absorbs its traffic, and import-side interdiction means a working URL is not evidence that a given lot will clear customs or matches its label.

• Provenance breaks during consolidation: batch and COA history tied to a closed vendor does not automatically carry over to a successor or 'alternative' storefront.
• Independent COA verification gains weight: third-party identity and purity testing (e.g. HPLC, mass spectrometry) becomes the primary objective signal when brand reputation resets.
• Label claims face import scrutiny: the CBP interdiction indicates that mis-manifested or 'RUO'-labeled human-use products are an active enforcement target, not a settled gray zone [1][2].
• Regulatory status is per-substance: a catalog can mix substances on different sides of the 503A Category 1/Category 2 line, so source evaluation is compound-specific [4].

The 2025-2026 wave is best read as a reclassification of the channel rather than the end of research-peptide supply. The FDA's PCAC process is actively sorting peptides into compoundable and non-compoundable buckets, the GLP-1 litigation is establishing precedent on who may make and sell these molecules, and CBP is enforcing at the border. For laboratory researchers, the durable implication is that sourcing decisions increasingly rest on documentation — verifiable COAs, batch traceability, and the current regulatory status of each specific substance — rather than on a vendor's longevity or marketing.

Trade coverage identifies at least eight, with the most prominent being Science.bio (closure announced January 27, 2026) and Peptide Sciences (closed March 6, 2026). Amino Asylum exited in December 2025 following federal guilty pleas reported by the DOJ and FDA. Several smaller suppliers are reported to have closed across the same window through a mix of voluntary wind-downs and enforcement-related exits; those specific names are trade-reported rather than independently confirmed here.

No. Science.bio announced its permanent closure on January 27, 2026; Peptide Sciences shut down later, on March 6, 2026. Some early summaries reversed this order — the corroborated sequence is Science.bio first, then Peptide Sciences.

Reporting points to three converging forces: an FDA enforcement escalation that produced 50+ warning letters in September 2025 focused on 'research use only' products advertised for human use [2]; a CBP interdiction of roughly 5,000 mis-manifested peptide shipments from China [1]; and 2025 litigation by Eli Lilly and Novo Nordisk against GLP-1 compounders and sellers [6]. Together these raised legal exposure and operating cost across the channel.

The FDA targeted products sold as 'research use only' where the advertising indicated the product was intended for human use. In the agency's framing, marketing that points toward human use undercuts the RUO designation and can place the product into the unapproved-drug category [2]. This is a labeling and intent question, not a chemical one.

According to STAT reporting, the FDA treats BPC-157 as an unapproved drug and, in 2023, moved to prohibit compounding pharmacies from supplying it, citing potential significant safety risks such as immunogenicity and incomplete safety data [3]. As of 2026, peptide Category 2 listings are under active review, so the precise status of individual substances can change.

It shifts the basis of evaluation from brand reputation to documentation. With fewer, larger suppliers and broken provenance chains, independent COA verification, batch traceability, and per-substance regulatory status become the primary objective signals for assessing a source. ChemVerify reports these facts; it does not advise on purchase or use.

• Are Research Peptides Legal? -> /learn/are-research-peptides-legal
• Research Use Only (RUO) Legal Status for Peptides: Complete Guide -> /learn/research-use-only-ruo-legal-status-for-peptides-complete-guide
• FDA Peptide Reclassification 2026: Category 1 -> /learn/fda-peptide-reclassification-2026-category-1
• Peptide Sciences Shutdown: Gray-Market Impact -> /learn/peptide-sciences-shutdown-gray-market-impact
• How to Verify a Peptide Vendor -> /learn/how-to-verify-peptide-vendor